Trimetazidine 35mg MR Tablets

Trimetazidine 35mg is a modified-release antianginal medicine used alongside other treatment for stable angina when symptoms remain inadequately controlled or other antianginal medicines are not tolerated.
Take the modified-release tablet with food and swallow it whole. Do not crush or chew it. Keep the timing consistent; modified-release strengths cannot be exchanged with conventional tablets solely by matching a daily milligram total.
Trimetazidine shifts cardiac energy metabolism towards glucose oxidation, which uses oxygen more efficiently than fatty-acid oxidation. This helps preserve cellular energy during myocardial ischaemia without a primary blood-pressure- or heart-rate-lowering action.
Nausea, abdominal discomfort, diarrhoea, headache or dizziness can occur. New tremor, stiffness, slowed movement, restless legs or unsteady walking needs prompt assessment because a medicine-related movement disorder is possible.
Do not use with Parkinson's disease, related movement disorders or severe kidney impairment. Older adults and people with moderately impaired kidneys can need a lower exposure. It is not treatment for an unstable chest-pain episode or a heart attack.
Can reduce angina episodes and improve exercise tolerance when added to ongoing stable-angina treatment. Cardiovascular risk reduction and emergency chest-pain treatment remain separate parts of care.
No. Trimetazidine is not a rapid-relief angina medicine. Follow the existing chest-pain action plan and seek emergency help for new, severe or persistent pain.
No. Its main action is metabolic. It does not primarily work by slowing the heart rate like a beta-blocker.
Trimetazidine can cause or worsen Parkinson-like movement symptoms. A new tremor, stiffness or shuffling gait should not be dismissed as normal ageing.
No. Its role is additional symptom control when other treatment is insufficient or not tolerated. It does not provide the same action as nitrates, beta-blockers or antiplatelets.
Stable angina: predictable chest discomfort caused by limited heart-muscle blood supply. Myocardial ischaemia: insufficient oxygen delivery to heart muscle. Metabolic agent: a medicine affecting cellular energy use. Glucose oxidation: energy production from glucose using oxygen. Parkinsonism: tremor, stiffness or slowed movement resembling Parkinson's disease.; AR: Trimetazidine 35mg أقراص ممتدة التحرر; FR: Trimetazidine 35mg comprimés à libération prolongée; PT: Trimetazidine 35mg comprimidos de libertação prolongada; ES: Trimetazidine 35mg comprimidos de liberación prolongada; RU: Trimetazidine 35mg таблетки пролонгированного высвобождения; ID: Trimetazidine 35mg tablet lepas lambat; VI: Trimetazidine 35mg viên nén giải phóng kéo dài; MS: Trimetazidine 35mg tablet pelepasan berpanjangan; TL: Trimetazidine 35mg tabletang may pinalawig na paglabas; ZH-SG: Trimetazidine 35mg 缓释片
International B2B Enquiry
Send a structured B2B enquiry for Trimetazidine 35mg MR Tablets under Cardiac Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Trimetazidine 35mg MR Tablets